CGA-IGC Partnership Announcement

CGA-IGC Partnership Announcement

LS CancerDiag entered a new partnership with The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

As we honored the #HereditaryCancerWeek last week, we took the occasion to announce our partnership with CGA-IGC.

The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer, CGA-IGC, is an organization established in 1995 that brings together colorectal surgeons, medical oncologists, gastroenterologists, researchers, geneticists, nurses, colorectal cancer registry coordinators, genetic counselors, psychologists, and all other health care professionals involved in the care of individuals with hereditary gastrointestinal cancer to improve understanding of the basic science and the clinical management of inherited gastrointestinal cancers.

The vision of the CGA-IGC is to eliminate morbidity and early mortality of hereditary gastrointestinal cancers.

CGA IGC Vision Statement

The CGA-IGC vision is very aligned with LS CancerDiag’s mission of empowering families and healthcare professionals to make better informed decisions for cancer prevention. And in terms of our values the company could hardly wish for a better suited partnership. Both organization share the deep wish to create and share knowledge in service of advancing this important field of research and to improve our understanding of the complexity related to  hereditary cancer predispositions.

CGA-IGC Annual Meeting 2022

The mission of the CGA-IGC is to advance science and clinical care of inherited gastrointestinal cancers through research and education as the leading authority in the Americas.

CGA-IGC Mission Statement

The highlight for the 2023 partnership will be to support the CGA-IGC Annual Meeting, taking place in Las Vegas from the 26th to the 28th of October, an event showcasing cutting-edge developments in the field, including groundbreaking research and clinical paradigm shifts. LS CancerDiag will also join this collaborative event that aims to share knowledge and up-to-date information on new developments in hereditary gastrointestinal cancer research, including implications in the prevention, diagnosis, and treatment of patients with hereditary cancer syndromes.

“We are pleased to partner with the LS CancerDiag and extremely grateful for their support. This allows us to continue being a key resource for individuals and institutions working in the field of inherited gastrointestinal cancer syndromes, including Lynch Syndrome, by supporting professional growth and improving patient outcomes by expanding access to up-to-date information of interest to the multidisciplinary healthcare team and researchers”, says 2023 CGA-IGC president & gastroenterologist, Dr. Peter Stanich.

“LS CancerDiag is privileged to support the significant efforts CGA-IGC is taking within the expert community around hereditary gastrointestinal cancer. We share the common purpose of improving cancer management through advanced science and clinical care; thus, we are pleased to contribute to their valuable efforts in providing a high-quality and accessible platform for educating, sharing knowledge, and finding resources”, says LS CancerDiag Head of Culture and Communication Philippe Arnez.

Through the alliance with CGA-IGC, LS CancerDiag wants to support the organization’s high-yield activities to its engaged, multidisciplinary members. Those activities encompass much more than the annual meeting, and include resources such as journal scans, webinars, and an own podcast.

The aim of CGA-IGC is to help its members, the hereditary cancer care professionals, in their daily practice, and LS CancerDiag is proud to be part of those efforts. After an initial engagement last year, we are looking forward to deepening our relationship with the CGA-IGC society and nurture this fruitful collaboration over the coming years.

LS CancerDiag CEO Niklas Lahti, and Head of Culture and Communication Philippe Arnez at the 2022 CGA Meeting
image/svg+xml

To learn more about CGA-IGC, please visit their website at https://www.cgaigc.com/

Recent Posts

Share:

Contact Us

  • For general inquiries:
    contact (at) lscancerdiag.com
  • For technical support:
    +358 40 6602622
  • LS CancerDiag Ltd
    Arabiankatu 12
    00560 Helsinki
    Finland

Privacy Policy

This document informs you about privacy issues such as the collection, storage, use and disclosure of personal information received from users of this Website, and of personal information received in the course of the provided services.

Contact

If you have any questions about this Privacy Policy, your data, or if you would like to exercise one of your data protection rights, please do not hesitate to contact our data protection officer at:

LS CancerDiag Ltd
Business ID 2558287-9
Arabiankatu 12
00560 Helsinki
Finland

Email: privacy@lscancerdiag.com

Data we may collect about you

If you are a website visitor, we may collect your name, email, and cookies.

If you are a patient, we may collect your name, date of birth, gender, ethnicity, nationality, identifiable genetic information, health-related information from your physician, specimen identification number and equivalent identifiers, family history and relationships.

If you are a customer, marketing contact, or job applicant, we may collect your name, contact details and relevant professional data.

If you are an employee or corporate-related member of LS CancerDiag Ltd, this privacy statement does not apply to you. You may contact LS CancerDiag Ltd for the relevant privacy notice.

How we receive your data

If you are a website visitor, customer, marketing contact, or job applicant, your data is collected by us with your consent.

If you are a patient, your data is collected by your healthcare facility or intermediary lab testing facility and send to us for diagnostic testing.

How we use your data

We look at the trend of our website visitors to understand how we can improve our online communication about our services. Some data may be visible, such as your cookies, and from where you access our website. Other information may not be visible to us.

We provide our services, such as diagnostic testing and analysis, to our customers, and keep them informed about our company updates.

We are building our network with marketing contacts to make sure our company updates and achievements are spread within the community.

Data from job applicants is kept with specific consent for future career opportunities, or deleted after completion of the interview process.

Data from patients is used for diagnostic testing, to provide the patient’s physician health-related information about the patient and its family. If the patient has provided informed consent to its healthcare facility, we may also use the patient data for further research to improve our internal diagnostic testing services, or acquire a deeper academic understanding about the specifics of the Lynch syndrome.

How we protect your data

We have implemented several technical and organizational measures to protect the identity of any of our data subjects.

We use only secured electronic tools, which acquired prior approval by our data protection officer, and which are subject to regular review and updates. We do not make use of automatic decision-making tools.

Within our organization, only authorized personnel are assigned to process specific types of data originating from patients, customers and marketing contacts, and employees and job applicants. All personnel, new or onboarding staff, consultants, external or technical advisers are only allowed to process data that is specifically required to fulfill their work-related purpose, and only when they have obtained prior authorization.

We are processing patient-related information under pseudonymized references to make sure no identifying information is revealed when used for diagnostic testing and, in those instances, where the results are used for further internal research purposes.

 

Regularly we audit, review, update and communicate our data protection policy documentation, risk assessment, breach policy, IT systems and policies, storage and retention documentation under guidance of our data protection officer together with the entire team, and we record the results in our data protection registry of records.

Do we share your data

We only share your data with sub-processors we have carefully vetted and are authorized by our data protection officer, to assist us in providing our diagnostic services, such as external electronic tools to store your data in protected clouds, or couriers to send your samples to the healthcare facility.

Unless explicitly authorized to do so by a legal obligation, we do not share your personal data with any other third parties.

Do we transfer your data

LS CancerDiag Ltd is based in Finland and does not transfer data from our website visitor, customer, marketing contact, job applicants or patient data outside the European Economic Area, unless your data is stored in Cloud services outside the European Economic Area. In those instances, we have ensured carefully the legal contractual requirements to make use of these services to fully protect the identity of the data subjects.

If LS CancerDiag Ltd has received patient data from a healthcare or intermediary lab testing facility within the European Economic Area, we will not transfer your data physically outside the Union.

In the event we have received patient data from a healthcare or intermediary lab testing facility outside the European Economic Area, we will transfer your data physically outside the Union, carefully and in compliance with the legal requirements for international transfers.

How long do we store your data

We retain data regarding our website visitors, that is identifiable in some nature, for maximum of one year. Website data, which is anonymous, is not subject to data protection laws and kept indefinitely.

Data regarding customers and marketing contacts, are kept for a duration of two to five years, depending on the nature of the business relationship. Each year this data will be reviewed and established if it is necessary to retain the data.

Data regarding job applicants will be kept throughout the interview process and deleted within sixty days after conclusion. In the event the job applicant wishes to remain in our database for future job opportunities, we will keep the data for a duration of maximum one year.

Health-related data from patients will be kept internally within our company for not longer than ten years.

How can I exercise my data protection rights?

As a website visitor, customer or marketing contact or job applicant, you have at all times the right to:

  • access your data and request copies of all processing activities concerning your data;
  • rectify information concerning any data about you that you believe is inaccurate;
  • request to be forgotten, to which we can comply under certain conditions: such as when we are not following a legal obligation from a National Authority, or reasons for public interest or public health;
  • request to restrict or object to processing, to which we can comply under certain conditions, such as when we are not following a legal obligation from a National Authority, or reasons for public interest or public health;
  • request a structured, commonly used and machine-readable format to transfer the data to another controller or directly to you (portability).

 

As a patient, you have in principle the same rights as stated above. However, in some instances we may not be able to comply because we are not your data controller. In those instances, may you contact us, we will refer to your healthcare facility and we will assist your data controller to the best of our abilities.

Complaints

Please feel free to consult us about your data protection rights, or any privacy matter related to you. Should you LS CancerDiag Ltd has not addressed your concerns in a satisfying manner, or you wish to report a complaint, you may contact the Data Protection Authority in Finland or in your country of residence.

Updates

This policy was last updated December 2023. LS CancerDiag Ltd will keep this privacy policy continuously under review and reserves the right to modify this document. LS CancerDiag Ltd advises you to regularly to consult this document for the latest updates.

Privacy Policy

Navigate

Follow us

Linkedin Twitter Facebook Youtube
Follow LS CancerDiag on F6S

Send message

Newsletter Subscription

X-Europe
bf_logo_blue_rgb
image (2)
ProHEALTH_accelerator_colour
EIT Health accelerated by - Web
StartupHealth
Previous
Next
X-Europe

Invest today!

LS CancerDiag has launched a funding round in collaboration with Springvest. 

The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world. 

Join our journey